Tag: Immunotherapy
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab
AI Can Reliably Predict Efficacy of Immune Checkpoint Inhibitor Therapy
SCORPIO machine learning system can predict certain outcomes across diverse cancer types and health care settings
Black Patients Have Similar Immune Checkpoint Inhibitor Effectiveness, Lower Toxicity
Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients
Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles
ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability
Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
Findings seen in patients previously treated with platinum-based chemotherapy and immunotherapy whose tumors highly expressed CEACAM5
Perioperative Nivolumab Beneficial for Resectable NSCLC
Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients
